207_Combined course Presentations

Relevant Questions::

Molecular evolution of resistance to treatment:  Acquired during therapy?  As a result of continuing mutagenesis?

 Already present in a clonal subpopulation within the tumours prior to the initiation of therapy?  Is resistance therefore a fait accompli—the time to recurrence is simply the interval required for the subclone to repopulate the lesion.?  Is the short time interval of recurrence due to the rapid expansion of the resistant subclone immediately following treatment initiation?  Required: Combination therapies targeting at least two different “processes” or “pathways”.